Renz Mang, Thomas Ruzicka, Helger Stege. Show Affiliations »
Abstract
Entities: Disease
Mesh： See more » Antibodies, Monoclonal/administration & dosageAntibodies, Monoclonal/adverse effectsBiopsyDisease ProgressionDrug Administration ScheduleFemaleHumansImmunosuppressive Agents/administration & dosageImmunosuppressive Agents/adverse effectsInfliximabInfusions, IntravenousLeg Ulcer/complicationsLeg Ulcer/pathologyMiddle AgedNecrosisOpportunistic Infections/immunologyRecurrenceRemission InductionStaphylococcal Infections/immunologyTumor Necrosis Factor-alpha/antagonists & inhibitorsVasculitis, Leukocytoclastic, Cutaneous/complicationsVasculitis, Leukocytoclastic, Cutaneous/drug therapyVasculitis, Leukocytoclastic, Cutaneous/pathologyWound Healing
Substances： See more » Antibodies, MonoclonalImmunosuppressive AgentsTumor Necrosis Factor-alphaInfliximab
Year: 2004 PMID： 15280860 DOI： 10.1016/j.jaad.2004.01.003
Source DB: PubMed Journal: J Am Acad Dermatol ISSN： 0190-9622 Impact factor: 11.527